Chris Ocampo
Head of Psychiatry, Neuroscience Clinical Development Abbvie
I have been at AbbVie since 2013 having spent the majority of my time in Clinical Development across various therapeutic areas including Solid Tumor Oncology, Immunology, General Medicine/Virology and Neuroscience. Since joining the Neuroscience group in 2023 I have worked on assets in neurodegeneration and psychiatry and became Head of Psychiatry Clinical Development in 2025.
Seminars
Thursday 17th September 2026
Panel Discussion: To What Degree Does Neuroplasticity Underpin Psychedelics Efficacy?
9:15 am
- Examining the evidence linking psychedelic induced synaptic and dendritic remodeling with changes in mood, cognition and emotional processing
- Exploring whether neuroplasticity is a mechanistic driver of efficacy or a downstream accompaniment to broader network level changes
- Comparing plasticity linked biomarkers, such as EEG signatures, sleep architecture shifts and neurotrophic factor changes, to determine which most reliably map onto clinical response
- Debating how much neuroplasticity is necessary, sufficient or even predictive for therapeutic benefit across different psychedelic and non psychedelic compounds
- Considering maladaptive behaviors underpinned by neuroplasticity in the brain
- How might we treat “neuroplastogens” differently: as a separate class
